$299 Million is the total value of Tamarack Advisers, LP's 28 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 88.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VSI | Sell | VITAMIN SHOPPE INCequity | $6,429,000 | +32.0% | 925,000 | -17.4% | 2.15% | -7.1% |
| LMNX | Sell | LUMINEX CORPequity | $2,335,000 | +16.9% | 79,089 | -16.5% | 0.78% | -17.7% |
| Exit | CVS US 04/20/18 C60call | $0 | – | -750 | -100.0% | 0.00% | – | |
| CERN | Exit | CERNER CORPequity | $0 | – | -45,000 | -100.0% | -1.24% | – |
| STE | Exit | STERIS PLCequity | $0 | – | -45,000 | -100.0% | -2.00% | – |
| CRME | Exit | CARDIOME PHARMA CORPequity | $0 | – | -1,875,000 | -100.0% | -2.07% | – |
| ALKS | Exit | ALKERMES PLCequity | $0 | – | -110,000 | -100.0% | -3.03% | – |
| QDEL | Exit | QUIDEL CORPequity | $0 | – | -165,000 | -100.0% | -4.07% | – |
| MDT | Exit | MEDTRONIC PLCequity | $0 | – | -190,000 | -100.0% | -7.25% | – |
| NVCR | Exit | NOVOCURE LTDequity | $0 | – | -1,115,000 | -100.0% | -11.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 31 | Q4 2023 | 100.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.